Clinical trials performed with IL‐17 blocking monoclonal antibodies have clearly shown that IL‐17 inhibition is an effective treatment for ankylosing spondylitis (AS), a disorder characterized by new bone formation.16, 17. This evidence concerns the gene IL17A and ankylosing spondylitis.